Nikhil I. Khushalani, MD - The Immunotherapy Story Continues for CSCC: Insights and Evidence on Advances in Resectable and Unresectable Disease

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/CPY865. CME/AAPA credit will be available until October 20, 2026. The Immunotherapy Story Continues for CSCC: Insights and Evidence on Advances in Resectable and Unresectable Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc. Disclosure information is available at the beginning of the video presentation.

You can listen to Nikhil I. Khushalani, MD - The Immunotherapy Story Continues for CSCC: Insights and Evidence on Advances in Resectable and Unresectable Disease online on Radio and Podcast. Open the player on this page to stream the available audio.

Nikhil I. Khushalani, MD - The Immunotherapy Story Continues for CSCC: Insights and Evidence on Advances in Resectable and Unresectable Disease is an episode from PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast by PeerView, 24 West 40th Street, Suite 950, New York, NY 10018.

This episode is 00:48:26 long.

This episode was published on Oct 30, 2025.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast when more episodes are available from the podcast feed.